Early off-label treatment during pandemics? A dilemma

Jan A. Roth; Tala Ballouz; Roger D. Kouyos; Manuel Battegay

doi:10.4414/smw.2020.20281

Viewpoint

Vol. 150 No. 1920 (2020)

Early off-label treatment during pandemics? A dilemma

Jan A. Roth
Tala Ballouz
Roger D. Kouyos
Manuel Battegay

DOI: https://doi.org/10.4414/smw.2020.20281
Cite this as:: Swiss Med Wkly. 2020;150:w20281
Published: 11.05.2020

References

Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. N Engl J Med. 2020;382(19):1851–2. doi:.https://doi.org/10.1056/NEJMe2005477
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99; Epub ahead of print. doi:.https://doi.org/10.1056/NEJMoa2001282
Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med. 2020;NEJMp2009457. doi:.https://doi.org/10.1056/NEJMp2009457
Simon GE, Platt R, Hernandez AF. Evidence from pragmatic trials during routine care - slouching toward a learning health system. N Engl J Med. 2020;382(16):1488–91. doi:.https://doi.org/10.1056/NEJMp1915448
Ladanie A, Ioannidis JPA, Stafford RS, Ewald H, Bucher HC, Hemkens LG. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. J Clin Epidemiol. 2018;94:35–45. doi:.https://doi.org/10.1016/j.jclinepi.2017.11.006

Publication image

How to Cite

1.

Roth JA, Ballouz T, Kouyos RD, Battegay M. Early off-label treatment during pandemics? A dilemma. Swiss Med Wkly [Internet]. 2020 May 11 [cited 2024 Apr. 19];150(1920):w20281. Available from: https://smw.ch/index.php/smw/article/view/2787

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

Peter Hengstler, Edouard Battegay, Jacques Cornuz, Heiner Bucher, Manuel Battegay, Evidence for prevention and screening: recommendations in adults , Swiss Medical Weekly: Vol. 132 No. 2728 (2002)
Kathrin Bausch, Jan A. Roth, Hans-H. Seifert, Andreas F. Widmer, Overuse of antimicrobial prophylaxis in low-risk patients undergoing transurethral resection of the prostate , Swiss Medical Weekly: Vol. 148 No. 0708 (2018)
Manuel Battegay, Luigia Elzi, Morbidity and mortality in HIV-infected individuals - a shift towards comorbidities , Swiss Medical Weekly: Vol. 139 No. 3940 (2009)
Gianluca Mauro Menghini, Robert Thurnheer, Christian R. Kahlert, Philipp Kohler, Fabian Grässli, Reto Stocker, Manuel Battegay, Danielle Vuichard-Gysin, Impact of shift work and other work-related factors on anti-SARS-CoV-2 spike-protein serum concentrations in healthcare workers after primary mRNA vaccination – a retrospective cohort study , Swiss Medical Weekly: Vol. 154 No. 3 (2024)

<< < 1 2 3

[1] Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. N Engl J Med. 2020;382(19):1851–2. doi:.https://doi.org/10.1056/NEJMe2005477

[2] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99; Epub ahead of print. doi:.https://doi.org/10.1056/NEJMoa2001282

[3] Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med. 2020;NEJMp2009457. doi:.https://doi.org/10.1056/NEJMp2009457

[4] Simon GE, Platt R, Hernandez AF. Evidence from pragmatic trials during routine care - slouching toward a learning health system. N Engl J Med. 2020;382(16):1488–91. doi:.https://doi.org/10.1056/NEJMp1915448

[5] Ladanie A, Ioannidis JPA, Stafford RS, Ewald H, Bucher HC, Hemkens LG. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. J Clin Epidemiol. 2018;94:35–45. doi:.https://doi.org/10.1016/j.jclinepi.2017.11.006